Gilead-Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study

Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study

吉利德科学(US:GILD) Businesswire·2025-10-19 06:30

核心观点 - Trodelvy在ASCENT-03三期研究中作为转移性三阴性乳腺癌一线治疗显示出无进展生存期具有高度统计学意义和临床意义的改善 [1] 临床研究结果 - 与化疗相比 Trodelvy在不适于PD-1/PD-L1抑制剂的转移性三阴性乳腺癌患者的一线治疗中表现出无进展生存期的显著改善 [1]